Survivin Expression May Affect The Neoadjuvantchemotherapy Response İn Breast Cancer Patients

Basit Öğe Kaydı
dc.authorid0000-0002-8559-2476en_US
dc.authorid0000-0003-2335-3354en_US
dc.authorid0000000345330620en_US
dc.contributor.authorEr, Zehra
dc.contributor.authorPeştereli, Hatice Elif
dc.contributor.authorTavlı, Lema
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorErdoğan, Gülgün
dc.contributor.authorEsen, Hacı Hasan
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorGündüz, Şeyda
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorDemircioğlu, Sinan
dc.date.accessioned2020-01-18T21:03:04Z
dc.date.available2020-01-18T21:03:04Z
dc.date.issued2017
dc.departmentNEÜ, Meram Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Anabilim Dalıen_US
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.description.abstractTo investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients. Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n52). Event -free survival (EFS) (defined as recurrence or metastasis free) analyze was performed. The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p>0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p0.038, p0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze. Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials.en_US
dc.identifier.citationDemircioğlu, S., Artaç, M., Korkmaz, L., Gündüz, S., Karaağaç, M., Esen, H H., Erdoğan, G., Bozcuk, H., Er, Z., Peştereli, H E., Tavlı, L. (2017). Survivin Expression May Affect The Neoadjuvant Chemotherapy Response in Breast Cancer Patients. Eastern Journal of Medicine, 22, 4, 147-154.en_US
dc.identifier.endpage154en_US
dc.identifier.issn1301-0883en_US
dc.identifier.issn1339-3886en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage147en_US
dc.identifier.urihttp://app.trdizin.gov.tr/publication/paper/detail/TWpZM05EZzVPUT09
dc.identifier.urihttps://hdl.handle.net/20.500.12452/1440
dc.identifier.volume22en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofEastern Journal of Medicineen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiş Hekimliğien_US
dc.subjectFarmakoloji ve Eczacılıken_US
dc.subjectToksikolojien_US
dc.subjectBreast canceren_US
dc.subjectKi-67en_US
dc.subjectneoadjuvant chemotherapyen_US
dc.subjectNF-kappaBen_US
dc.subjectpathological responseen_US
dc.subjectsurvivinen_US
dc.titleSurvivin Expression May Affect The Neoadjuvantchemotherapy Response İn Breast Cancer Patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sinan demircioğlu.pdf
Boyut:
443.86 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text/Tam Metin
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu